IPG is pretty much holding it together as it waits to complete its merger with Omnicom, reporting a 3.5% decline in organic growth in Q2 - not great but in line with forecasts - as account losses ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...